AbbVie's antibody-drug conjugate misses mark in Phase III GBM trial

In a second setback for glioblastoma multiforme patients this month, AbbVie said its depatuxizumab mafodotin missed the primary endpoint of improving overall survival in the Phase III INTELLANCE-1 for newly diagnosed EGFR-amplified GBM.

AbbVie Inc. (NYSE:ABBV) management had touted its

Read the full 398 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE